Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTF1057
- Development stage
- Unknown
- Lead developer
- HighTide Therapeutics
- Modality
- Small Molecules
01
Overview
HTF1057 is a small molecule mitochondrial uncoupler being developed by HighTide Therapeutics for the treatment of neurodegenerative diseases. Mitochondrial dysfunction is a hallmark of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. By acting as a mitochondrial uncoupler, HTF1057 aims to reduce oxidative stress and prevent calcium overload within the mitochondria, potentially protecting neurons from degeneration. As of August 2025, the candidate is in Phase 1 clinical development, representing an expansion of HighTide's pipeline beyond its core focus on metabolic and digestive diseases.
02
Targets
OXPHOS (Mitochondrial OXPHOS complexes)
Beyond the preview
Go deeper on HTF1057.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTF1057.